Topical Corticosteroid Rx-To-OTC Switch Safety To Be Considered By NDAC
This article was originally published in The Tan Sheet
Executive Summary
The Nonprescription Drugs and Dermatologic & Ophthalmic Drugs (DODAC) advisory committees will discuss guidelines on adequate safety information when considering Rx-to-OTC switches of topical corticosteroids during a March 24 meeting
You may also be interested in...
Antiseptic meeting
Anti-infective Drugs Advisory Committee meeting scheduled for May 11 has been cancelled, according to committee hotline. Panelists were to discuss microbiologic endpoints as substitutes for effectiveness in clinical trials intended to address the safety and efficacy of antiseptic health care drug products (1"The Tan Sheet" March 22, 2004, In Brief). FDA has not announced a new date for the meeting...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands